, | |||||
(State or other jurisdiction of incorporation) | (Commission file number) | (IRS Employer Identification No.) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | |
Toronto Stock Exchange |
Item 2.02 | Results of Operations and Financial Condition. |
BAUSCH HEALTH COMPANIES INC. | |
By: | /s/ Paul S. Herendeen |
Paul S. Herendeen | |
Executive Vice President, Chief Financial Officer |
Investor/Media Contact: | |
Arthur Shannon | |
arthur.shannon@bauschhealth.com | |
(514) 856-3855 | |
(877) 281-6642 (toll free) |
• | Second-Quarter 2019 Financial Results |
◦ | Revenues of $2.152 Billion |
◦ | GAAP Net Loss of $171 Million |
◦ | Adjusted EBITDA (non-GAAP)1 of $880 Million |
◦ | GAAP Cash Flow From Operations of $339 Million |
• | Sixth Consecutive Quarter of Total Company Organic Revenue Growth1,2 |
• | Delivered Total Company Reported Revenue Growth of 1%; Organic Revenue Growth1,2 of 3% Compared to Second Quarter of 2018 |
◦ | Bausch + Lomb/International Segment Delivered Eleventh Consecutive Quarter of Organic Revenue Growth1,2 |
◦ | Salix Segment Reported Total Quarterly Revenue in Excess of $500 Million for the First Time |
• | Raised Full-Year 2019 Guidance Ranges |
• | The Bausch + Lomb/International segment comprised approximately 56% of the Company’s revenue in the second quarter of 2019 |
◦ | Reported revenue in the Bausch + Lomb/International segment decreased nominally compared to the second quarter of 2018; revenue in this segment grew organically1,2 by 4% compared to the second quarter of 2018, due to an increase in volume across most of the business units, particularly in Global Consumer and Global Vision Care |
◦ | Delivered eleventh consecutive quarter of organic revenue growth1,2 |
◦ | LOTEMAX® SM (Loteprednol Etabonate Ophthalmic Gel) 0.38% for the treatment of postoperative inflammation and pain following ocular surgery was launched in the U.S. in April 2019 |
◦ | Bausch + Lomb ULTRA® Multifocal for Astigmatism contact lenses, the first and only multifocal toric lens available as a standard offering in the eye care professional's fit set, was launched in the U.S. in June 2019 |
• | The Salix segment comprised approximately 24% of the Company’s revenue in the second quarter of 2019 |
◦ | XIFAXAN® revenue increased by 21% compared to the second quarter of 2018 |
◦ | Entered into a license agreement with the University of California, Los Angeles to develop and commercialize a novel compound for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis |
◦ | Entered into an exclusive license agreement with Mitsubishi Tanabe Pharma to develop and commercialize a late-stage investigational sphingosine 1-phosphate (S1P) modulator for the treatment of inflammatory bowel disease |
• | The Ortho Dermatologics segment comprised approximately 6% of the Company’s revenue in the second quarter of 2019 |
◦ | Revenues in the Global Solta business increased by 41% compared to the second quarter of 2018, driven by continued strong demand of Thermage® FLX in Asia Pacific following the launch in the region |
◦ | DUOBRII™ Lotion for the topical treatment of plaque psoriasis in adults was launched in the U.S. in June 2019 |
• | Increased research and development by approximately 24%, or $23 million, compared to the second quarter of 2018 |
• | Refinanced $1.5 billion of 2023 Senior Unsecured Notes |
• | Reduced debt by approximately $100 million in the second quarter of 2019 |
(in millions) | 2Q 2019 | 2Q 2018 | Reported Change | Reported Change | Change at Constant Currency3 | Organic1, 2 Change | |||||||||
Segment | |||||||||||||||
Bausch + Lomb/International | $1,208 | $1,209 | ($1) | — | % | 3 | % | 4 | % | ||||||
Salix | $509 | $441 | $68 | 15 | % | 15 | % | 12 | % | ||||||
Ortho Dermatologics | $122 | $141 | ($19) | (13 | %) | (13 | %) | (13 | %) | ||||||
Diversified Products | $313 | $337 | ($24) | (7 | %) | (7 | %) | (7 | %) | ||||||
Total Revenues | $2,152 | $2,128 | $24 | 1 | % | 3 | % | 3 | % |
• | Raised full-year revenues from $8.35 - $8.55 billion to the range of $8.40 - $8.60 billion |
• | Raised full-year Adjusted EBITDA (non-GAAP)1 from $3.40 - $3.55 billion to the range of $3.425 - $3.575 billion |
• | Bausch Health’s cash, cash equivalents and restricted cash were $880 million at June 30, 2019 |
• | The Company’s availability under its revolving credit facility was approximately $905 million at June 30, 2019 |
• | Basic weighted average shares outstanding for the quarter were 352.1 million shares. Diluted weighted average shares outstanding for the quarter were 356.5 million shares4 |
Date: | Tuesday, August 6, 2019 |
Time: | 8:00 a.m. EDT |
Webcast: | http://ir.bauschhealth.com/events-and-presentations |
Participant Event Dial-in: | +1 (888) 317-6003 (United States) |
+1 (412) 317-6061 (International) | |
+1 (866) 284-3684 (Canada) | |
Participant Passcode: | 2275809 |
Replay Dial-in: | +1 (877) 344-7529 (United States) |
+1 (412) 317-0088 (International) | |
+1 (855) 669-9658 (Canada) | |
Replay Passcode: | 10132759 (replay available until August 13, 2019) |
• | Restructuring and integration costs: The Company has incurred restructuring costs as it implemented certain strategies, which involved, among other things, improvements to its infrastructure and operations, internal reorganizations and impacts from the divestiture of assets and businesses. In addition, in connection with its acquisition of certain assets of Synergy, the Company has incurred certain severance and integration costs which were not essential to complete, close or report the acquisition. With regard to infrastructure and operational improvements which the Company has taken to improve efficiencies in the businesses and facilities, these tend to be costs intended to right size the business or organization that fluctuate significantly between periods in amount, size and timing, depending on the improvement project, reorganization or transaction. With regard to the severance and integration costs associated with the acquisition of certain assets of Synergy, these costs are specific to the acquisition itself and provided no benefit to the ongoing operations of the Company. As a result, the Company does not believe that such costs (and their impact) are truly representative of the underlying business. The Company believes that the adjustments of these items provide supplemental information with regard to the sustainability of the Company's operating performance, allow for a comparison of the financial results to historical operations and forward-looking guidance and, as a result, provide useful supplemental information to investors. |
• | Acquired in-process research and development costs: The Company has excluded expenses associated with acquired in-process research and development, as these amounts are inconsistent in amount and frequency and are significantly impacted by the timing, size and nature of acquisitions. Furthermore, as these amounts are associated with |
• | Asset impairments: The Company has excluded the impact of impairments of finite-lived and indefinite-lived intangible assets, as well as impairments of assets held for sale, as such amounts are inconsistent in amount and frequency and are significantly impacted by the timing and/or size of acquisitions and divestitures. The Company believes that the adjustments of these items correlate with the sustainability of the Company's operating performance. Although the Company excludes intangible impairments from its non-GAAP expenses, the Company believes that it is important for investors to understand that intangible assets contribute to revenue generation. |
• | Goodwill impairments: The Company has excluded the impact of goodwill impairment. When the Company has made acquisitions where the consideration paid was in excess of the fair value of the net assets acquired, the remaining purchase price is recorded as goodwill. For assets that we developed ourselves, no goodwill is recorded. Goodwill is not amortized but is tested for impairment. For periods prior to Jan. 1, 2018, the amount of goodwill impairment is measured as the excess of the carrying value of a reporting unit's goodwill over its implied fair value. However, in January 2017, new accounting guidance was issued which simplifies the subsequent measurement of an impairment to goodwill. Under the new guidance, which the Company early adopted effective Jan. 1, 2018, the amount of goodwill impairment is measured as the excess of a reporting unit's carrying value over its fair value. Management excludes these charges in measuring the performance of the Company and the business. |
• | Share-based compensation: The Company has excluded the impact of costs relating to share-based compensation. The Company believes that the exclusion of share-based compensation expense assists investors in the comparisons of operating results to peer companies. Share-based compensation expense can vary significantly based on the timing, size and nature of awards granted. |
• | Acquisition-related costs and adjustments excluding amortization of intangible assets: The Company has excluded the impact of acquisition-related costs and fair value inventory step-up resulting from acquisitions as the amounts and frequency of such costs and adjustments are not consistent and are significantly impacted by the timing and size of its acquisitions. In addition, the Company has excluded the impact of acquisition-related contingent consideration non-cash adjustments due to the inherent uncertainty and volatility associated with such amounts based on changes in assumptions with respect to fair value estimates, and the amount and frequency of such adjustments is not consistent and is significantly impacted by the timing and size of the Company's acquisitions, as well as the nature of the agreed-upon consideration. |
• | Loss on extinguishment of debt: The Company has excluded loss on extinguishment of debt as this represents a cost of refinancing our existing debt and is not a reflection of our operations for the period. Further, the amount and frequency of such charges are not consistent and are significantly impacted by the timing and size of debt financing transactions and other factors in the debt market out of management's control. |
• | Other Non-GAAP charges: The Company has excluded certain other amounts, including legal and other professional fees incurred in connection with recent legal and governmental proceedings, investigations and information requests respecting certain of our distribution, marketing, pricing, disclosure and accounting practices, litigation and other matters, and net gain on sale of assets. In addition, the Company has excluded certain other expenses, such as IT infrastructure investment, that are the result of other, non-comparable events to measure operating performance. These events arise outside of the ordinary course of |
• | Amortization of intangible assets: The Company has excluded the impact of amortization of intangible assets, as such amounts are inconsistent in amount and frequency and are significantly impacted by the timing and/or size of acquisitions. The Company believes that the adjustments of these items correlate with the sustainability of the Company's operating performance. Although the Company excludes amortization of intangible assets from its non-GAAP expenses, the Company believes that it is important for investors to understand that such intangible assets contribute to revenue generation. Amortization of intangible |
• | Foreign currency exchange rates: Although changes in foreign currency exchange rates are part of our business, they are not within management's control. Changes in foreign currency exchange rates, however, can mask positive or negative trends in the business. The impact for changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period. |
• | Acquisitions, divestitures and discontinuations: In order to present period-over-period organic revenues (non-GAAP) on a comparable basis, revenues associated with acquisitions, divestitures and discontinuations are adjusted to include only revenues from those businesses and assets owned during both periods. Accordingly, organic revenue (non-GAAP) growth/change excludes from the current period, revenues attributable to each acquisition for twelve months subsequent to the day of acquisition, as there are no revenues from those businesses and assets included in the comparable prior period. Organic revenue (non-GAAP) growth/change excludes from the prior period (but not the current period), all revenues attributable to each divestiture and discontinuance during the twelve months prior to the day of divestiture or discontinuance, as there are no revenues from those businesses and assets included in the comparable current period. |
Bausch Health Companies Inc. | Table 1 | |||||||||||||||
Condensed Consolidated Statements of Operations | ||||||||||||||||
For the Three and Six Months Ended June 30, 2019 and 2018 | ||||||||||||||||
(unaudited) | ||||||||||||||||
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
(in millions) | 2019 | 2018 | 2019 | 2018 | ||||||||||||
Revenues | ||||||||||||||||
Product sales | $ | 2,122 | $ | 2,100 | $ | 4,111 | $ | 4,065 | ||||||||
Other revenues | 30 | 28 | 57 | 58 | ||||||||||||
2,152 | 2,128 | 4,168 | 4,123 | |||||||||||||
Expenses | ||||||||||||||||
Cost of goods sold (excluding amortization and impairments of intangible assets) | 580 | 584 | 1,104 | 1,144 | ||||||||||||
Cost of other revenues | 14 | 10 | 27 | 23 | ||||||||||||
Selling, general and administrative | 651 | 642 | 1,238 | 1,233 | ||||||||||||
Research and development | 117 | 94 | 234 | 186 | ||||||||||||
Amortization of intangible assets | 488 | 741 | 977 | 1,484 | ||||||||||||
Goodwill impairments | — | — | — | 2,213 | ||||||||||||
Asset impairments | 13 | 301 | 16 | 345 | ||||||||||||
Restructuring and integration costs | 4 | 7 | 24 | 13 | ||||||||||||
Acquisition-related contingent consideration | 20 | (6 | ) | (1 | ) | (4 | ) | |||||||||
Other expense, net | 8 | — | 5 | 12 | ||||||||||||
1,895 | 2,373 | 3,624 | 6,649 | |||||||||||||
Operating income (loss) | 257 | (245 | ) | 544 | (2,526 | ) | ||||||||||
Interest income | 3 | 3 | 7 | 6 | ||||||||||||
Interest expense | (409 | ) | (435 | ) | (815 | ) | (851 | ) | ||||||||
Loss on extinguishment of debt | (33 | ) | (48 | ) | (40 | ) | (75 | ) | ||||||||
Foreign exchange and other | 3 | (9 | ) | 3 | 18 | |||||||||||
Loss before benefit from (provision for) income taxes | (179 | ) | (734 | ) | (301 | ) | (3,428 | ) | ||||||||
Benefit from (provision for) income taxes | 9 | (138 | ) | 83 | (23 | ) | ||||||||||
Net loss | (170 | ) | (872 | ) | (218 | ) | (3,451 | ) | ||||||||
Net income attributable to noncontrolling interest | (1 | ) | (1 | ) | (5 | ) | (3 | ) | ||||||||
Net loss attributable to Bausch Health Companies Inc. | $ | (171 | ) | $ | (873 | ) | $ | (223 | ) | $ | (3,454 | ) |
Bausch Health Companies Inc. | Table 2 | |||||||||||||||
Reconciliation of GAAP Net Loss to Adjusted Net Income (non-GAAP) | ||||||||||||||||
For the Three and Six Months Ended June 30, 2019 and 2018 | ||||||||||||||||
(unaudited) | ||||||||||||||||
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
(in millions) | 2019 | 2018 | 2019 | 2018 | ||||||||||||
Net loss attributable to Bausch Health Companies Inc. | $ | (171 | ) | $ | (873 | ) | $ | (223 | ) | $ | (3,454 | ) | ||||
Non-GAAP adjustments: (a) | ||||||||||||||||
Amortization of intangible assets | 488 | 741 | 977 | 1,484 | ||||||||||||
Asset impairments | 13 | 301 | 16 | 345 | ||||||||||||
Goodwill impairments | — | — | — | 2,213 | ||||||||||||
Restructuring and integration costs | 4 | 7 | 24 | 13 | ||||||||||||
Acquired in-process research and development costs | 7 | — | 8 | 1 | ||||||||||||
Acquisition-related costs and adjustments (excluding amortization of intangible assets) | 24 | (6 | ) | 12 | (4 | ) | ||||||||||
Loss on extinguishment of debt | 33 | 48 | 40 | 75 | ||||||||||||
IT infrastructure investment | 5 | — | 9 | — | ||||||||||||
Legal and other professional fees | 11 | 15 | 19 | 20 | ||||||||||||
Net loss (gain) on sale of assets | 1 | — | (9 | ) | — | |||||||||||
Litigation and other matters | 1 | (1 | ) | 3 | 10 | |||||||||||
Other | (3 | ) | 1 | (7 | ) | — | ||||||||||
Tax effect of non-GAAP adjustments | (41 | ) | 94 | (139 | ) | (64 | ) | |||||||||
Total non-GAAP adjustments | 543 | 1,200 | 953 | 4,093 | ||||||||||||
Adjusted net income attributable to Bausch Health Companies Inc. (non-GAAP) | $ | 372 | $ | 327 | $ | 730 | $ | 639 |
Bausch Health Companies Inc. | Table 2a | |||||||||||||||
Reconciliation of GAAP to Non-GAAP Financial Information | ||||||||||||||||
For the Three and Six Months Ended June 30, 2019 and 2018 | ||||||||||||||||
(unaudited) | ||||||||||||||||
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
(in millions) | 2019 | 2018 | 2019 | 2018 | ||||||||||||
Cost of goods sold reconciliation: | ||||||||||||||||
GAAP Cost of goods sold (excluding amortization and impairments of intangible assets) | $ | 580 | $ | 584 | $ | 1,104 | $ | 1,144 | ||||||||
Fair value inventory step-up resulting from acquisitions (a) | (4 | ) | — | (5 | ) | — | ||||||||||
Adjusted cost of goods sold (excluding amortization and impairments of intangible assets) (non-GAAP) | $ | 576 | $ | 584 | $ | 1,099 | $ | 1,144 | ||||||||
Selling, general and administrative reconciliation: | ||||||||||||||||
GAAP Selling, general and administrative | $ | 651 | $ | 642 | $ | 1,238 | $ | 1,233 | ||||||||
IT infrastructure investment (b) | (5 | ) | — | (9 | ) | — | ||||||||||
Legal and other professional fees (c) | (11 | ) | (15 | ) | (19 | ) | (20 | ) | ||||||||
Other Selling, general and administrative (d) | 2 | — | 2 | 1 | ||||||||||||
Adjusted selling, general and administrative (non-GAAP) | $ | 637 | $ | 627 | $ | 1,212 | $ | 1,214 | ||||||||
Amortization of intangible assets reconciliation: | ||||||||||||||||
GAAP Amortization of intangible assets | $ | 488 | $ | 741 | $ | 977 | $ | 1,484 | ||||||||
Amortization of intangible assets (e) | (488 | ) | (741 | ) | (977 | ) | (1,484 | ) | ||||||||
Adjusted amortization of intangible assets (non-GAAP) | $ | — | $ | — | $ | — | $ | — | ||||||||
Goodwill impairments reconciliation: | ||||||||||||||||
GAAP Goodwill impairments | $ | — | $ | — | $ | — | $ | 2,213 | ||||||||
Goodwill impairments (f) | — | — | — | (2,213 | ) | |||||||||||
Adjusted goodwill impairments (non-GAAP) | $ | — | $ | — | $ | — | $ | — | ||||||||
Restructuring and integration costs reconciliation: | ||||||||||||||||
GAAP Restructuring and integration costs | $ | 4 | $ | 7 | $ | 24 | $ | 13 | ||||||||
Restructuring and integration costs (g) | (4 | ) | (7 | ) | (24 | ) | (13 | ) | ||||||||
Adjusted restructuring and integration costs (non-GAAP) | $ | — | $ | — | $ | — | $ | — | ||||||||
Asset impairments reconciliation: | ||||||||||||||||
GAAP Asset impairments | $ | 13 | $ | 301 | $ | 16 | $ | 345 | ||||||||
Asset impairments (i) | (13 | ) | (301 | ) | (16 | ) | (345 | ) | ||||||||
Adjusted asset impairments (non-GAAP) | $ | — | $ | — | $ | — | $ | — | ||||||||
Acquisition-related contingent consideration reconciliation: | ||||||||||||||||
GAAP Acquisition-related contingent consideration | $ | 20 | $ | (6 | ) | $ | (1 | ) | $ | (4 | ) | |||||
Acquisition-related contingent consideration (a) | (20 | ) | 6 | 1 | 4 | |||||||||||
Adjusted acquisition-related contingent consideration (non-GAAP) | $ | — | $ | — | $ | — | $ | — | ||||||||
Other expense, net reconciliation: | ||||||||||||||||
GAAP Other expense, net | $ | 8 | $ | — | $ | 5 | $ | 12 | ||||||||
Net (loss) gain on sale of assets (j) | (1 | ) | — | 9 | — | |||||||||||
Acquisition-related costs (a) | — | — | (8 | ) | — | |||||||||||
Litigation and other matters (k) | (1 | ) | 1 | (3 | ) | (10 | ) | |||||||||
Acquired in-process research and development costs (l) | (7 | ) | — | (8 | ) | (1 | ) | |||||||||
Other (d) | 1 | (1 | ) | 5 | (1 | ) | ||||||||||
Adjusted other expense (non-GAAP) | $ | — | $ | — | $ | — | $ | — |
Bausch Health Companies Inc. | Table 2a (continued) | |||||||||||||||
Reconciliation of GAAP to Non-GAAP Financial Information | ||||||||||||||||
For the Three and Six Months Ended June 30, 2019 and 2018 | ||||||||||||||||
(unaudited) | ||||||||||||||||
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
(in millions) | 2019 | 2018 | 2019 | 2018 | ||||||||||||
Loss on extinguishment of debt reconciliation: | ||||||||||||||||
GAAP Loss on extinguishment of debt | $ | (33 | ) | $ | (48 | ) | $ | (40 | ) | $ | (75 | ) | ||||
Loss on extinguishment of debt (m) | 33 | 48 | 40 | 75 | ||||||||||||
Adjusted loss on extinguishment of debt (non-GAAP) | $ | — | $ | — | $ | — | $ | — | ||||||||
Benefit from (provision for) income taxes reconciliation: | ||||||||||||||||
GAAP Benefit from (provision for) income taxes | $ | 9 | $ | (138 | ) | $ | 83 | $ | (23 | ) | ||||||
Tax effect of non-GAAP adjustments (n) | (41 | ) | 94 | (139 | ) | (64 | ) | |||||||||
Adjusted provision for income taxes (non-GAAP) | $ | (32 | ) | $ | (44 | ) | $ | (56 | ) | $ | (87 | ) |
Bausch Health Companies Inc. | Table 2b | ||||||||||||||||
Reconciliation of GAAP Net Loss to Adjusted EBITDA (non-GAAP) | |||||||||||||||||
For the Three and Six Months Ended June 30, 2019 and 2018 | |||||||||||||||||
(unaudited) | |||||||||||||||||
Three Months Ended | Six Months Ended | ||||||||||||||||
June 30, | June 30, | ||||||||||||||||
(in millions) | 2019 | 2018 | 2019 | 2018 | |||||||||||||
Net loss attributable to Bausch Health Companies Inc. | $ | (171 | ) | $ | (873 | ) | $ | (223 | ) | $ | (3,454 | ) | |||||
Interest expense, net | 406 | 432 | 808 | 845 | |||||||||||||
(Benefit from) provision for income taxes | (9 | ) | 138 | (83 | ) | 23 | |||||||||||
Depreciation and amortization | 531 | 784 | 1,063 | 1,570 | |||||||||||||
EBITDA | 757 | 481 | 1,565 | (1,016 | ) | ||||||||||||
Adjustments: | |||||||||||||||||
Asset impairments | 13 | 301 | 16 | 345 | |||||||||||||
Goodwill impairments | — | — | — | 2,213 | |||||||||||||
Restructuring and integration costs | 4 | 7 | 24 | 13 | |||||||||||||
Acquired in-process research and development costs | 7 | — | 8 | 1 | |||||||||||||
Acquisition-related costs and adjustments (excluding amortization of intangible assets) | 24 | (6 | ) | 12 | (4 | ) | |||||||||||
Loss on extinguishment of debt | 33 | 48 | 40 | 75 | |||||||||||||
Share-based compensation | 27 | 22 | 51 | 43 | |||||||||||||
Other adjustments: | |||||||||||||||||
IT infrastructure investment | 5 | — | 9 | — | |||||||||||||
Legal and other professional fees (a) | 11 | 15 | 19 | 20 | |||||||||||||
Net loss (gain) on sale of assets | 1 | — | (9 | ) | — | ||||||||||||
Litigation and other matters | 1 | (1 | ) | 3 | 10 | ||||||||||||
Other | (3 | ) | 1 | (7 | ) | — | |||||||||||
Adjusted EBITDA (non-GAAP) | $ | 880 | $ | 868 | $ | 1,731 | $ | 1,700 |
Bausch Health Companies Inc. | Table 3a | ||||||||||||||||||||||||||||||||||
Organic Growth (non-GAAP) - by Segment | |||||||||||||||||||||||||||||||||||
For the Three Months Ended June 30, 2019 and 2018 | |||||||||||||||||||||||||||||||||||
(unaudited) | |||||||||||||||||||||||||||||||||||
Calculation of Organic Revenue for the Three Months Ended | |||||||||||||||||||||||||||||||||||
June 30, 2019 | June 30, 2018 | Change in Organic Revenue | |||||||||||||||||||||||||||||||||
Revenue as Reported | Changes in Exchange Rates (a) | Acquisition | Organic Revenue (Non-GAAP) (b) | Revenue as Reported | Divestitures and Discontinuations | Organic Revenue (Non-GAAP) (b) | |||||||||||||||||||||||||||||
(in millions) | Amount | Pct. | |||||||||||||||||||||||||||||||||
Bausch + Lomb/International | |||||||||||||||||||||||||||||||||||
Global Vision Care | $ | 216 | $ | 7 | $ | — | $ | 223 | $ | 207 | $ | (1 | ) | $ | 206 | $ | 17 | 8 | % | ||||||||||||||||
Global Surgical | 177 | 7 | — | 184 | 182 | (2 | ) | 180 | 4 | 2 | % | ||||||||||||||||||||||||
Global Consumer Products | 371 | 11 | — | 382 | 369 | (4 | ) | 365 | 17 | 5 | % | ||||||||||||||||||||||||
Global Ophtho Rx | 172 | 5 | — | 177 | 178 | — | 178 | (1 | ) | (1 | )% | ||||||||||||||||||||||||
International Rx | 272 | 7 | — | 279 | 273 | (5 | ) | 268 | 11 | 4 | % | ||||||||||||||||||||||||
Total Bausch + Lomb/International | 1,208 | 37 | — | 1,245 | 1,209 | (12 | ) | 1,197 | 48 | 4 | % | ||||||||||||||||||||||||
Salix | 509 | — | (17 | ) | 492 | 441 | (3 | ) | 438 | 54 | 12 | % | |||||||||||||||||||||||
Ortho Dermatologics | |||||||||||||||||||||||||||||||||||
Ortho Dermatologics(c) | 77 | — | — | 77 | 109 | — | 109 | (32 | ) | (29 | )% | ||||||||||||||||||||||||
Global Solta | 45 | 1 | — | 46 | 32 | — | 32 | 14 | 44 | % | |||||||||||||||||||||||||
Total Ortho Dermatologics | 122 | 1 | — | 123 | 141 | — | 141 | (18 | ) | (13 | )% | ||||||||||||||||||||||||
Diversified Products | |||||||||||||||||||||||||||||||||||
Neurology and Other | 175 | — | — | 175 | 216 | (1 | ) | 215 | (40 | ) | (19 | )% | |||||||||||||||||||||||
Generics(c) | 112 | — | — | 112 | 90 | — | 90 | 22 | 24 | % | |||||||||||||||||||||||||
Dentistry(c) | 26 | — | — | 26 | 31 | — | 31 | (5 | ) | (16 | )% | ||||||||||||||||||||||||
Total Diversified Products | 313 | — | — | 313 | 337 | (1 | ) | 336 | (23 | ) | (7 | )% | |||||||||||||||||||||||
Totals | $ | 2,152 | $ | 38 | $ | (17 | ) | $ | 2,173 | $ | 2,128 | $ | (16 | ) | $ | 2,112 | $ | 61 | 3 | % |
Bausch Health Companies Inc. | Table 3b | ||||||||||||||||||||||||||||||||||
Organic Growth (non-GAAP) - by Segment | |||||||||||||||||||||||||||||||||||
For the Six Months Ended June 30, 2019 and 2018 | |||||||||||||||||||||||||||||||||||
(unaudited) | |||||||||||||||||||||||||||||||||||
Calculation of Organic Revenue for the Six Months Ended | |||||||||||||||||||||||||||||||||||
June 30, 2019 | June 30, 2018 | Change in Organic Revenue | |||||||||||||||||||||||||||||||||
Revenue as Reported | Changes in Exchange Rates (a) | Acquisition | Organic Revenue (Non-GAAP) (b) | Revenue as Reported | Divestitures and Discontinuations | Organic Revenue (Non-GAAP) (b) | |||||||||||||||||||||||||||||
(in millions) | Amount | Pct. | |||||||||||||||||||||||||||||||||
Bausch + Lomb/International | |||||||||||||||||||||||||||||||||||
Global Vision Care | $ | 419 | $ | 16 | $ | — | $ | 435 | $ | 402 | $ | (1 | ) | $ | 401 | $ | 34 | 8 | % | ||||||||||||||||
Global Surgical | 344 | 16 | — | 360 | 353 | (3 | ) | 350 | 10 | 3 | % | ||||||||||||||||||||||||
Global Consumer Products | 695 | 29 | — | 724 | 699 | (10 | ) | 689 | 35 | 5 | % | ||||||||||||||||||||||||
Global Ophtho Rx | 333 | 10 | — | 343 | 321 | — | 321 | 22 | 7 | % | |||||||||||||||||||||||||
International Rx | 535 | 24 | — | 559 | 537 | (12 | ) | 525 | 34 | 6 | % | ||||||||||||||||||||||||
Total Bausch + Lomb/International | 2,326 | 95 | — | 2,421 | 2,312 | (26 | ) | 2,286 | 135 | 6 | % | ||||||||||||||||||||||||
Salix | 954 | — | (23 | ) | 931 | 863 | (6 | ) | 857 | 74 | 9 | % | |||||||||||||||||||||||
Ortho Dermatologics | |||||||||||||||||||||||||||||||||||
Ortho Dermatologics(c) | 177 | — | — | 177 | 220 | — | 220 | (43 | ) | (20 | )% | ||||||||||||||||||||||||
Global Solta | 83 | 2 | — | 85 | 61 | — | 61 | 24 | 39 | % | |||||||||||||||||||||||||
Total Ortho Dermatologics | 260 | 2 | — | 262 | 281 | — | 281 | (19 | ) | (7 | )% | ||||||||||||||||||||||||
Diversified Products | |||||||||||||||||||||||||||||||||||
Neurology and Other | 361 | — | — | 361 | 425 | (2 | ) | 423 | (62 | ) | (15 | )% | |||||||||||||||||||||||
Generics(c) | 216 | — | — | 216 | 180 | — | 180 | 36 | 20 | % | |||||||||||||||||||||||||
Dentistry(c) | 51 | — | — | 51 | 62 | — | 62 | (11 | ) | (18 | )% | ||||||||||||||||||||||||
Total Diversified Products | 628 | — | — | 628 | 667 | (2 | ) | 665 | (37 | ) | (6 | )% | |||||||||||||||||||||||
Totals | $ | 4,168 | $ | 97 | $ | (23 | ) | $ | 4,242 | $ | 4,123 | $ | (34 | ) | $ | 4,089 | $ | 153 | 4 | % |
Bausch Health Companies Inc. | Table 4 | ||||||||
Other Financial Information | |||||||||
(unaudited) | |||||||||
(in millions) | June 30, 2019 | December 31, 2018 | |||||||
Cash Balances | |||||||||
Cash and cash equivalents | $ | 878 | $ | 721 | |||||
Restricted cash | 2 | 2 | |||||||
Cash, cash equivalents and restricted cash | $ | 880 | $ | 723 | |||||
Debt Balances | |||||||||
Senior Secured Credit Facilities: | |||||||||
2023 Revolving Credit Facility | $ | 150 | $ | 75 | |||||
June 2025 Term Loan B Facility | 4,029 | 4,269 | |||||||
November 2025 Term Loan B Facility | 1,384 | 1,456 | |||||||
Senior Secured Notes | |||||||||
5.75% Senior Secured Notes due August 2027 | 493 | — | |||||||
All other Senior Secured Notes | 4,953 | 4,948 | |||||||
Senior Unsecured Notes: | |||||||||
5.625% Senior Unsecured Notes due December 2021 | — | 697 | |||||||
5.50% Senior Unsecured Notes due March 2023 | 400 | 995 | |||||||
5.875% Senior Unsecured Notes due May 2023 | 1,539 | 3,229 | |||||||
8.50% Senior Unsecured Notes due January 2027 | 1,757 | 738 | |||||||
7.00% Senior Unsecured Notes due June 2028 | 740 | — | |||||||
7.25% Senior Unsecured Notes due June 2029 | 740 | — | |||||||
All other Senior Unsecured Notes | 7,878 | 7,886 | |||||||
Other | 16 | 12 | |||||||
Total long-term debt and other, net of premiums, discounts and issuance costs | 24,079 | 24,305 | |||||||
Plus: Unamortized premiums, discounts and issuance costs | 290 | 327 | |||||||
Total long-term debt and other | $ | 24,369 | $ | 24,632 | |||||
Maturities and Mandatory Payments of Debt Obligations | |||||||||
Remainder of 2019 | $ | 4 | $ | 228 | |||||
2020 | 203 | 303 | |||||||
2021 | 303 | 1,003 | |||||||
2022 | 1,553 | 1,553 | |||||||
2023 | 4,109 | 6,348 | |||||||
2024 | 2,303 | 2,303 | |||||||
2025 | 10,632 | 10,632 | |||||||
2026 - 2029 | 5,262 | 2,262 | |||||||
Total debt obligations | $ | 24,369 | $ | 24,632 | |||||
2019 | 2018 | ||||||||
Cash provided by operating activities - Three months ended June 30, | $ | 339 | $ | 222 | |||||
Cash provided by operating activities - Six months ended June 30, | $ | 752 | $ | 660 |
Document |
Aug. 06, 2019 |
---|---|
Cover page. | |
Document Type | 8-K |
Document Period End Date | Aug. 06, 2019 |
Entity Registrant Name | Bausch Health Companies Inc. |
Entity Incorporation, State or Country Code | A1 |
Entity Address, Country | CA |
Entity File Number | 001-14956 |
Entity Tax Identification Number | 98-0448205 |
Entity Address, Address Line One | 2150 St. Elzéar Blvd. West |
Entity Address, City or Town | Laval |
Entity Address, State or Province | QC |
Entity Address, Postal Zip Code | H7L 4A8 |
City Area Code | 514 |
Local Phone Number | 744-6792 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Shares, No Par Value |
Trading Symbol | BHC |
Security Exchange Name | NYSE |
Entity Emerging Growth Company | false |
Entity Central Index Key | 0000885590 |
Amendment Flag | false |
#))S#7&7C'$$Q A>+9IS#76>ZI8)@BH()GG\)<9RM?
M!<&L RJ!KS;,=;;Q51#,-J""9Y\BWVZ__4 P05_P[%.8Z]Q_DS%,X'^,XMFG
M,->Y_XXA&'"69-&YV<[X!Y/7IE?146C3!+I6[2*$YJ9>^F3JU:89GR7_E5R>>W?6)Q
M.'J/21E%Q9Z2*%NXP[+??L5?Z9R%V*_1#M>H-EBCZ7;=3J?5ZKKGUI8AK:.#
MWC
'K.![,>=%#(\='E\Q4??TEUG/7H(PK8>_R43]-<#JUV5?
M4$L#!!0 ( '8Y!D\+C]@#(0$ %<$ 3 6T-O;G1E;G1?5'EP97-=
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M2_#0#28A3#,*BNQ&CB>65H*2ZA,O>43H6\>"/4E
][T3
M6"9S$-KW(#)A!,P'LT&%G;T$H+#,<5P;$?FG&OP*RIRRWYQ[##RUX7$&Z+9"
MOX"9 @-0:EU:T:#0R>_"MP'&W=MLC.-VGG+O*V):L,3C)'U%OV+*?3"$O&,6
M>-ILRAKVTHC9'9+;=#G H$E82IZF&5+"Q6OXCK'L+$NV6!R#<8G.($S>Z17R_*
MQ[0]X"T[P):+["[!Z5BQ?E(\]O(5I*)45FT781[Q\VCW6*U"%"I^R=]G5,
MU5$LF:-:G.@:_6.K&E2[I* :!=5J$52;;Y)Q%E72S3?IW5 JKA2UD>A;1\E2
M:1I*K,SI48G"D>@K*]\':KS*NS>UD:>*,93J?$K>A>8H VAEJ'U/NG,5_\7M
M]:FR1/33)J]2!R1*;+MU8JE*7VTSF6+N2S"BN#V6B$%M$K5U.PO+4AZ)^<>%
M1M-$6#HJX7%+;\CZ-+M=:@EX\7-5-OVO)05!\U[JF,$M;!H5)E<)3[$%F "59@+)*FC(*
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MSQRS[3WJO%H]7P &-@YFAHMT9,V<[ZB&*^#4!P(KN;M\)A0"ZBVO&V+$B0=ZH*Z
MF+MT;M$FI*JJM)X8D6HS(Q=9UB2[J(.*,,-;&0Z?<'Z!FWE:6Y8@7Z&R,?
MDFSE]2=]U8SJO-5JD;BZDUK^E=#;YN3Y83B.=6*NK*.J@*370&C=#J,%C&"*
MPOMQ--@S65$!5+FTT)*$=;)MN\\:@TL#TVZR,K6O-V]EU]E5J/;\H\R]+*";
M6"X7PM=&WI)34VSS;X;O$7;-X]
M.]JOB8&)@0_/P!?;5^02]U:9>ZM4[Y3+M5,ES?&)DX2>^QRX+/Y>_9L:SM+Q
M.:GQ_1EXOAP]S).U.X IJ8ND#4#TKT_4-\FH!J?GFTXDNJ7%CQG;_)R@Z/;;
MB6!R.N.&ST:.RXP)M\?"8]+&CS!%FQF!ZPK;>BA_Z5N=S'2SQF"E^X4U@-
MDW&/^? H4XY& B\7^ C\1M_NLQD,P#&9*V:.ZPO\XT[8 3R'^WB==!>O7/5>
M;IOK/1C^X%8 WP0>4$+=,X7Y3ZP'Q@'#?"Q6OL,,W.@6PX'5<1$/; 8O
8UV(< T+/)%&!:__M1H-=3WE$+GV?<5JKH*QF2V
M/I M_1R3(5Y^VS%/;H)H^GH\S^+9'Z:S+.HOTZYLMZ@_BHE$XFG()ZFXF'UX
MQ+W&_6&9A^-BO<;ZLS0S=2E#MC1/5#Q?ZZ=NV0T^\5-OC\\ZV^.S]MF'^WQ6
MN^6H8*4_ZW2CN^9I?<_Z=O\ AP371P+GV_JU\]4QSEOEA-B_!+FD43%Q%)"=
M_37R3U9/>AN5(.F0*Q@.R ==NB,?=.F.?/>Z[!ZRC&)9/N9*A?R=P